Clinical Trial Update: Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating selinexor (KPT-330) with liposomal doxorubicin for relapsed/refractory multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Selinexor (selinexor)
• liposomal doxorubicin (doxorubicin liposomal)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-02-19